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Abstract
Background: Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumour necrosis
factor cytokine family that induces apoptosis upon binding to its death domain containing receptors, TRAIL
receptor 1 (DR4) and TRAIL receptor 2 (DR5). Expression of TRAIL receptors is higher in colorectal carcinoma (CRC)
as compared to normal colorectal mucosa and targeted therapy with TRAIL leads to preferential killing of tumor
cells sparing normal cells.
Methods: We investigated the expression of TRAIL and its receptors in a tissue microarray cohort of 448 Middle
Eastern CRC. We also studied the correlation between TRAIL receptors and various clinico-pathological features
including key molecular alterations and overall survival.
Results: CRC subset with TRAIL-R1 expression was associated with a less aggressive phenotype characterized by
early stage (p = 0.0251) and a histology subtype of adenocarcinomas (p = 0.0355). Similarly CRC subset with TRAIL-
R2 expression was associated with a well-differentiated tumors (p < 0.0001), histology subtype of adenocarcinomas
(p = 0.0010) and tumors in left colon (p = 0.0009). Over expression of pro apoptotic markers: p27KIP1 and KRAS4A
isoforms was significantly higher in CRC subset with TRAIL-R1 and TRAIL-R2 expression; TRAIL-R1 expression was
also associated with cleaved caspase-3(p = 0.0011). Interestingly, TRAIL-R2 expression was associated with a
microsatellite stable (MS–S/L) phenotype (p = 0.0003) and with absence of KRAS mutations (p = 0.0481).
Conclusion: TRAIL-R1 expression was an independent prognostic marker for better survival in all CRC samples and
even in the CRC group that received adjuvant therapy. The biological effects of TRAIL in CRC models, its
enhancement of chemosensitivity towards standard chemotherapeutic agents and the effect of endogenous TRAIL
receptor levels on survival make TRAIL an extremely attractive therapeutic target.
Introduction
Colorectal Cancer (CRC) is a major cause of mortality
and morbidity worldwide. In Saudi Arabia, the incidence
of CRC is increasing. According to the latest statistics,
CRC is the second most common cancer among Saudi
males and the third most common among Saudi females
[1]. Currently available therapeutic approaches for CRC
are less effective, and thus the prognosis is poor. Despite
a growing number of publications about biomarkers that
give information on disease outcome, the best prognos-
tic factors are still simple clinical parameters like num-
ber of lymph nodal metastasis, presence of distant
metastasis, tumour grade and AJCC stage. Prognostic
biomarkers might especially be useful for hypothesis
testing for their relevance as predictive markers, as tar-
gets for therapy and for the selection of patients for
adjuvant treatment [2].
Apoptosis, or programmed cell death, is a major con-
trol mechanism by which cells die if DNA damage is not
repaired [3]. Apoptosis is an essential biochemical
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pathway for normal tissue homeostasis, cellular differen-
tiation, and development. Derangements of normal apop-
totic mechanisms provide a growth advantage to cancer
cells [4]. The understanding of apoptosis has provided
the basis for novel targeted therapies that can induce
death in cancer cells or sensitize them to established
cytotoxic agents and radiation therapy [5]. In addition, as
apoptosis usually does not elicit host inflammatory or
immune response, this type of cell death is the preferred
way of cancer cell killing by various treatments. Accord-
ingly, selectively inducing apoptosis in tumour cells is
gaining recognition as a promising therapeutic approach
for many cancers [6]. Tumour necrosis factor-related
apoptosis-inducing ligand (TRAIL or Apo2 ligand) is a
member of the tumour necrosis factor (TNF) cytokine
family that induces apoptosis upon binding to its death
domain containing receptors, TRAIL receptor 1 (death
receptor 4, DR4) and TRAIL receptor 2 (death receptor
5, DR5) [7]. The TRAIL receptors, TRAIL-R1 and
TRAIL-R2, are highly expressed in many cancer cells
including CRC [8-10]. A further three TRAIL receptors
exist, which are unable to induce apoptosis and act as
decoys. Decoy receptors 1 (DcR1) and 2 (DcR2), similar
to TRAIL-R1 and TRAIL-R2, are expressed on the cell
surface. Thus, overexpression of either DcR1 or DcR2
confers protection against TRAIL-induced apoptosis
[11,12]. The fifth TRAIL receptor is osteoprotegerin
(OPG), a secreted, low affinity receptor for TRAIL
[11,12]. Binding of TRAIL to TRAIL-R1 and TRAIL-R2
induces trimerization of TRAIL-R1 and TRAIL-R2 [13].
The trimerized TRAIL-R1 and TRAIL-R2 bind to FADD,
which recruits caspase 8 and initiates a proteolysis cas-
cade that eventually leads to cell death by apoptosis.
Many cancer cells are resistant to death receptor induced
apoptosis [4]. The mechanisms of resistance include the
presence of decoy receptors for TRAIL [12], the loss of
TRAIL receptor expression [14], the overexpression of
inhibitory proteins in signal transduction pathways such
as FLICE-inhibitory protein [14], and the mutation of
TRAIL-R2 gene [15-18].
Oncogenic mutations such as ras may enhance expres-
sion of TRAIL receptors; potentially sensitizing these
tumors to TRAIL based therapies [19-21]. Constitutively
activated Ras increases the tumorigenic potential of cells
because it causes deregulation of important intracellular
signaling pathways [22]. Activated RAS mediates its bio-
logical activity through interaction with various down-
stream effector targets, thus activating pathways like
MEK, PI3K, and Rho GTPases [22,23]. RAS regulates a
RAF-MEK-ERK1/2 kinase cascade and this pathway is
found to be active in human colon adenocarcinomas
cells [24] as well as in human colorectal tumors [25].
Drosopoulos et al. [21] have shown transformation of
the colon cell line Caco-2 by ras oncogenes sensitizes
these cells to TRAIL induced apoptosis by causing spe-
cific MEK-dependent up-regulation of TRAIL-R1 and
TRAIL-R2. Nesterov A et al. [20] have demonstrated
that normal cells are sensitized to TRAIL when TRAIL-
R2 is up regulated by overexpression of c-myc or onco-
genic ras mutants. Thus, RAS-MEK-ERK1/2 signaling
pathway can sensitize cells to TRAIL-induced apoptosis
by up-regulating TRAIL-R1, TRAIL-R2 and TRAIL-
based therapeutic strategies using TRAIL agonists could
be used in cases of human colon cancers bearing RAS
mutations. Therefore, we also sought to explore the
potential link between expression of TRAIL and its
receptors with KRAS alterations in CRC.
The aims of the present study were: (a) to determine
the TRAIL/TRAIL receptor expression pattern in nor-
mal and neoplastic colon epithelium; (b) to correlate
immunohistochemical expression patterns with KRAS
alterations, microsatellite instability and pro apoptotic
markers; (c) to correlate immunohistochemical expres-
sion patterns with overall survival.
Results
Expression of TRAIL and its receptors TRAIL-R1 and
TRAIL-R2
Incidence of TRAIL-R1, TRAIL-R2 and TRAIL ligand
expression in CRC was 85.5% (331/387), 59.4(217/365)
and 31.5% (127/403) respectively [Figure 1]. These inci-
dences are within the wide ranges reported earlier -
TRAIL: 37.5% to 83%, TRAIL-R1:58.1% to 100.0% and
TRAIL-R2: 40.3% to 100% [26-31]. Incidence of non-
interpretable tumor spots for TRAIL, TRAIL-R1 and
TRAIL R2 ranged from 10 to 18%. Tumor spots were
deemed not interpretable if they had insufficient tumor
cells, loss of tissue in the spot, or an abundance of
necrotic tissue. Expression of TRAIL and its receptors
was also evaluated in colorectal adenomas and adjacent
colorectal mucosa [Figure 2]. Both TRAIL-R1 and
TRAIL-R2 expression was significantly higher in both
colorectal adenomas [TRAIL-R1 96.11 ± 78.82
(p = 0.0312); TRAIL-R2 59.17 ± 49.69(p = 0.0027)] and
carcinoma [TRAIL-R1 173.91 ± 61.20(P < 0.00001);
TRAIL-R2 115.63 ± 95.76(p = < 0.0001)] as compared
to normal colorectal mucosa (TRAIL-R1 52.13 ± 42.48;
TRAIL-R2 24.57 ± 38.77). In addition, there was a sig-
nificant difference in expression of both TRAIL-R1
(p = 0.0006) and TRAIL-R2 (p = < 0.0001) between col-
orectal adenomas and carcinoma [Figure 3B and 3C].
Similarly, TRAIL expression was significantly higher in
carcinoma (132.87 ± 64.23; p < 0.0001) and adenomas
(129.01 ± 38.59; p < 0.0001) as compared to normal col-
orectal mucosa (48.59 ± 66.07). However, there was no
difference in TRAIL expression between adenomas and
carcinomas (p = 0.6822; Figure 3A). Thus the TRAIL
system may play a key role in colorectal carcinogenesis.
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Association of TRAIL, TRAIL-R1 and TRAIL-R2 with
clinico-pathological parameters
TRAIL-R1 was associated with histology subtype of ade-
nocarcinomas (p = 0.0355), early AJCC stage (p =
0.0251) and a trend of higher expression was noted with
well-differentiated tumors (p = 0.0887). No association
was seen with age, gender and tumor site (Table 1).
Similarly, TRAIL-R2 was associated with histology sub-
type of adenocarcinomas (p = 0.0010, tumors in the left
colon (p = 0.0009) and a significantly higher expression
was noted with well-differentiated tumors (p < 0.0001).
No associations were seen with age, gender and tumor
stage (Table 2). TRAIL ligand expression was not asso-
ciated with any of the clinico-pathological parameters
(see Additional File 1 Table S1).
Association of TRAIL, TRAIL-R1 and TRAIL-R2 with KRAS
mutations and KRAS splice variants KRAS4A and KRAS4B
TRAIL-R2 expression was significantly higher in the
CRC subset lacking KRAS mutations as compared to
CRC with KRAS mutations (p = 0.0481; Figure 4). Inter-
estingly, both TRAIL-R1(p < 0.0001) and TRAIL-R2(p <
0.0001) showed a highly significant association with the
pro-apoptotic KRAS4A isoform. However, TRAIL-R1
expression did not show any correlations with KRAS
mutations and KRAS4B isoform (Table 1 &2). TRAIL
expression did not show any associations with KRAS
mutations or expression of KRAS splice variants (see
Additional File 1 Table S1).
Associations of TRAIL, TRAIL-R1 and TRAIL-R2 with
microsatellite instability, cleaved caspase 3 and p27kip1
p27kip1 expression was significantly associated with both
TRAIL-R1 (p = 0.0024) and TRAIL-R2 (p < 0.0001;
Table 1 &2). CRC with expression of TRAIL-R1 but not
TRAIL-R2 or TRAIL also showed expression of cleaved
caspase3 (p = 0.0011). Although TRAIL-R2 was asso-
ciated with a phenotype of microsatellite stable (MSI-
S/L) tumors (p = 0.0003), no associations were seen
between TRAIL-R1 or TRAIL and microsatellite
instability status.
Overall survival in all patients, selected stage subgroups
and combination groups of TRAIL receptors
CRC with low TRAIL-R1 expression also showed a poor
5 year overall survival of 53.9% as compared to 68.1%
with high TRAIL-R1 expression (p = 0.0124; Figure 5A).
Similarly, CRC with low TRAIL-R2 expression also
Figure 1 Tissue microarray-based immunohistochemical analysis of TRAIL receptors TRAIL-R1 and TRAIL-R2 in CRC patients. CRC array
spots showing overexpression of TRAIL-R1 (A) and TRAIL-R2 (C). In contrast, other CRC tissue array spots showing low expression of TRAIL-R1 (B)
and TRAIL-R2 (D). 20 ×/0.70 objective on an Olympus BX 51 microscope (Olympus America Inc, Center Valley, PA, USA), with the inset showing a
40 ×/0.85 aperture magnified view of the same
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showed a poor 5 year overall survival of 57.6% as com-
pared to 67.3% with high TRAIL-R2 expression (p =
0.0211; Figure 5B). TRAIL expression did not show any
prognostic significance (p = 0.2901). To exclude that the
observed prognostic difference were caused by classical
prognostic factors of CRC, we performed a multivariate
analysis (Cox proportional hazards) with histological
subtype, tumor grade, tumor stage, age, gender and
microsatellite instability status as variables (Table 3). In
the multivariate analysis, only TRAIL-R1 expression
retained its significance. The relative risk was 1.84 (for
low TRAIL-R1 expression (95% CI 1.10 - 3.02; p =
0.0273) and 6.56 for high stage group III-IV (95% CI
3.67- 12.78; p = < 0.0001). Thus, TRAIL-R1 was an
independent prognostic marker in Middle Eastern Col-
orectal Carcinoma. To exclude that TRAIL-R1 is not a
readout of KRAS-4A or p27 we reanalyzed our data and
did a Cox proportional hazards model where we
included age, gender, Stage, Grade, KRAS-4A, p27 and
TRAIL-R1 expression (see Additional File 1 Table S2).
In a Cox proportional Hazards model, the independent
prognostic significance of TRAIL-R1 was weakened (p =
0.0883). However, AJCC stage, p27 and KRAS4A still
remained independent prognostic markers.
Although TRAIL-R1 expression was significantly more
in early stage tumors, a vast majority of Stage III & IV
tumors (82%) also showed TRAIL-R1 expression. Both
TRAIL-R1 (p = 0.0060) and TRAIL-R2 (p = 0.0263) were
associated with better outcome only in the advanced Stage
group (III and IV; see Additional File 2). When stage II
and III were taken together only TRAIL-R2 expression
was associated with better overall survival (p = 0.0088);
TRAIL-R1 expression was not significant (p = 0.2508; see
Additional File 3). Co-expression of TRAIL-R1 and
TRAIL-R2 was seen in 56.85% of the CRC( 191/336) and
was associated with a good survival (p = 0.0107; see Addi-
tional File 4) which remained significant in multivariate
analysis (Cox proportional hazards) with TRAIL-R1/R2
co-expression, tumor grade, tumor stage, age and gender
as variables (see Additional File 1 Table S3).
TRAIL death receptors and response to adjuvant therapy
The availability of 220 CRC from affected individuals
who had undergone adjuvant therapy: chemotherapy
Figure 2 Tissue microarray-based immunohistochemical analyses of TRAIL receptors TRAIL-R1 and TRAIL-R2 in CRC carcinogenesis. A
progressive increase on TRAIL-R1 expression was seen from normal colorectal mucosa (A) to adenoma (B) to carcinoma(C). Similarly, a
progressive increase on TRAIL-R2 expression was seen from normal colorectal mucosa (D) to adenoma (E) to carcinoma (F).
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and/or radiotherapy, allowed us to investigate the possi-
ble impact of TRAIL-R1 on response to adjuvant ther-
apy. For this analysis, we first stratified the individuals
into two groups: (i) CRC patient who have received
adjuvant therapy (n = 220), and (ii) CRC patient who
have been treated by surgical resection only and have
not received adjuvant therapy (n = 90). There was a
Figure 3 Box plot of TRAIL, TRAIL-R1 and TRAILR2 expression
in cancer, adenoma, and normal samples of colorectal patients.
(A) Using Student’s t-test, the mean ± SD of TRAIL expression in
normal colorectal mucosa (48.59 ± 66.07), adenoma (129.01 ± 38.59)
and cancer (132.87 ± 64.23) and showed a significant association
with cancer versus normal (p < 0.0001) and adenoma versus normal
(p < 0.0001). (B) Using Student’s t-test, the mean ± SD of TRAIL-R1
expression in normal colorectal mucosa (52.13 ± 42.48), adenoma
(96.11 ± 78.82), cancer (173.91 ± 61.20) showed a significant
association with cancer versus normal (p < 0.0001), adenoma versus
normal(p = 0.0312) and adenoma versus cancer(p = 0.0006). (C)
Using Student’s t-test, the mean ± SD of TRAIL-R2 expression in
normal colorectal mucosa (24.57 ± 38.77), adenoma (59.17 ± 49.69)
and cancer (115.63 ± 95.76) showed a significant association with
cancer versus normal (p < 0.0001), adenoma versus normal(p =
0.0027) and adenoma versus cancer(p < 0.0001).
Table 1 Clinico-pathological characteristics and TRAIL-R1






N % N % N %
Total Number of Cases 387 331 85.5 56 14.5
Age
< = 50 years 126 32.6 110 87.3 16 12.7 0.4870
> 50 years 261 67.4 221 84.7 40 15.3
Gender
Male 193 49.9 167 86.5 26 13.5 0.5773
Female 194 50.1 164 84.5 30 15.5
Tumour Site
Left colon 324 83.7 276 85.2 48 14.8 0.6576
Right colon 63 16.3 55 87.3 8 12.7
Histological Type
Adenocarcinoma 334 86.3 291 87.1 43 12.9 0.0355
Mucinous Carcinoma 53 13.7 40 75.5 13 24.5
Tumour Stage
I 55 15.0 53 96.4 2 3.6 0.0251
II 126 34.2 105 83.3 21 16.7
III 141 38.3 121 85.8 20 14.2
IV 46 12.5 36 78.3 10 21.7
Differentiation
Well 33 8.5 30 90.9 3 9.1 0.0887
Moderate 284 73.4 247 87.0 37 13.0
Poor 70 18.1 54 77.1 16 22.9
KRAS Mutation
Present 75 28.3 67 89.3 8 10.7 0.7407
Absent 190 71.7 167 87.9 23 12.1
K-RAS 2A
High expression 155 46.7 150 96.8 5 3.2 < 0.0001
Low expression 177 53.3 142 80.2 35 19.8
Cleaved-Caspase 3
High expression 172 49.9 160 93.0 12 7.0 0.0011
Low expression 173 50.1 141 81.5 32 18.5
P27 (Nuc)
High expression 139 38.4 130 93.5 9 6.5 0.0024
Low expression 223 61.6 185 83.0 38 17.0
MSI-Molecular
MSI-H 67 18.7 56 83.6 11 16.4 0.4731
MSI-S/L 292 81.3 254 87.0 38 13.0
Overall Survival
5 Years 68.1 53.9 0.0124
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statistically significant difference in survival between
individuals with tumors with TRAIL-R1 overexpression
versus those with reduced expression (p = 0.0033; see
Additional File 5). To exclude that the observed prog-
nostic difference was caused by classical prognostic fac-
tors of CRC we performed a multivariate analysis (Cox
proportional hazards) with TRAIL-R1 expression, tumor
grade, tumor stage, age and gender as variables (see
Additional File 1 Table S4). We found that the prognos-
tic value of TRAIL-R1 expression in adjuvant treated
individuals was independent of these factors. Similarly,
TRAIL-R2 expression was also associated with trend
towards better outcome in the adjuvant treated CRC
subgroup (p = 0.0998) but no association with outcome
was seen in the group which did not receive adjuvant
therapy.
Discussion
We conducted this study to examine the relations of
TRAIL and it receptors: TRAIL-R1 and TRAIL-R2 with
clinical, pathologic, molecular characteristics and patient
survival in Saudi colorectal cancers. Expression of
TRAIL-R1 or TRAIL-R2 was associated with a less
aggressive phenotype characterized by an early AJCC
stage and well-differentiated tumors. TRAIL-R2 expres-
sion was associated with microsatellite stable phenotype
and with absence of KRAS mutations. TRAIL-R1 but
not TRAIL-R2 was an independent prognostic marker
for better survival.
Using immunohistochemistry, we have studied the
expression of TRAIL and its receptors in Saudi CRC;
incidence of TRAIL R1, TRAIL-R2 and TRAIL expres-
sion was 85.5%, 59.4% and 31.5% respectively. In agree-
ment with earlier studies, we have also observed a
progressive increase in expression of TRAIL and its
receptors: TRAIL-R1 and TRAIL-R2 in colorectal carci-
noma and noted a strong association of TRAIL -R1 or
TRAIL-R2 expression with differentiation and an early
stage. The prognostic implication of TRAIL receptor
expression is the subject of intensive investigation as
malignant cells are more sensitive to TRAIL- induced
apoptosis than their benign counterparts are and this
potentially affects the future management of patients
[32-34]. Furthermore, our data indicates that high
TRAIL-R1 expression was an independent prognostic
marker for better survival in Saudi CRC patients. TRAIL-
R2 was also associated significantly with better outcome
but failed to remain significant in multivariate analysis.
TRAIL-R1 expression was also associated with better
outcome in the following subgroups: Stage III and IV (p
= 0.0060) and CRC subgroup who received adjuvant
therapy(p = 0.0033). To elucidate the role of TRAIL
expression further analysis was done in the following
subgroup: CRC subgroup with high co-expression of
TRAIL and TRAIL-R1 and CRC subgroup with high co-
expression of TRAIL and TRAIL-R2. Both these combi-
nation groups were not associated with outcome (data
not shown). Thus, TRAIL ligand co-expression with
TRAIL receptors does not influence the outcome.
These findings are in agreement with earlier studies by
Starter et al [26] where TRAIL-R1 expression was
Table 2 Clinico-pathological characteristics and TRAIL-R2






N % N % N %
Total Number of Cases 365 217 59.4 148 40.6
Age
< = 50 years 121 33.1 71 58.7 50 41.3 0.8320
> 50 years 244 66.9 146 59.8 98 40.2
Gender
Male 172 47.1 101 58.7 71 41.3 0.7883
Female 193 52.9 116 60.1 77 39.9
Tumour Site
Left colon 309 84.7 195 63.1 114 36.9 0.0009
Right colon 56 15.3 22 39.3 34 60.7
Histological Type
Adenocarcinoma 323 88.5 202 62.5 121 37.5 0.0010
Mucinous Carcinoma 42 11.5 15 35.7 27 64.3
Tumour Stage
I 46 13.3 33 71.7 13 28.3 0.2842
II 117 33.9 65 55.6 52 44.4
III 137 39.7 84 61.3 53 38.7
IV 45 13.0 28 62.2 17 37.8
Differentiation
Well 28 7.7 22 78.6 6 21.4 < 0.0001
Moderate 276 75.6 176 63.8 100 36.2
Poor 61 16.7 19 31.1 42 68.9
KRAS Mutation
Present 67 29.9 41 61.2 26 38.8 0.0481
Absent 157 70.1 117 74.5 40 25.5
K-RAS 2A (cyto)
High expression 160 46.8 128 80.0 32 20.0 < 0.0001
Low expression 182 53.2 82 45.1 100 54.9
Cleaved-Caspase 3
High expression 164 49.8 109 66.5 55 33.5 0.1209
Low expression 165 50.2 96 58.2 69 41.8
P27 (Nuc)
High expression 135 40.2 102 75.6 33 24.4 < 0.0001
Low expression 201 59.8 105 52.2 96 47.8
MSI-Molecular
MSI-H 66 19.8 28 42.4 38 57.6 0.0003
MSI-S/L 267 80.2 178 66.7 89 33.3
Overall Survival
5 Years 67.3 57.6 0.0211
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associated with a better disease free survival in a cohort
of 129 Stage II and III CRC [26]. Granci et al. [28] stu-
died the TRAIL receptors TRAIL-R 1, -2, -3 and -4
expression by immunohistochemistry in metastatic stage
IV CRC and found that concomitant low/medium-
TRAIL-R1 and high TRAIL-R3 expression in primary
CRC is significantly associated with a poor response to
5-FU-based first-line chemotherapy and with a shorter
progression-free survival. Surprisingly, high TRAIL R1
was associated with worse disease free survival and over-
all survival in 376 CRC patients with Stage III [30].
Ullenhag et al. [29] analyzed FLICE inhibitory protein
(c-FLIP) and TRAIL receptors(TRAIL-R1 and R-2) in
476 CRC of all Stage groups(I to IV): Overexpression of
Figure 4 Box plot analysis of TRAIL-R1 and TRAIL-R2 expression in KRAS mutated versus non-mutated colorectal patients. (A) Using
Student’s t-test, the mean ± SD of TRAIL-R1 expression in KRAS mutated (181.28 ± 61.33)and non mutated (181.25 ± 63.92).However, this
difference in expression was not statistically significant (p = 0.9824). (B Using Student’s t-test, the mean ± SD of TRAIL-R2 expression in KRAS
mutated (113.36 ± 92.45) and not mutated (140.00 ± 92.26).There was statistically significant difference in expression (p = 0.0466).
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FLIPL, (the long form of FLICE inhibitory protein) but
not TRAIL-R1 or TRAIL-R2, was an independent prog-
nostic factor for shorter disease free survival. In an
attempt to explain these conflicting results of TRAIL
and its pro-apoptotic receptors in CRC, we offer the fol-
lowing explanations: a) differences and heterogeneity in
samples studied: sample size, ethnic differences, different
Stage groups, tumor site- colon or rectal tumors, type of
treatment- surgery and/or chemo/radiotherapy; b) differ-
ences in scoring system could be another important rea-
son for this difference. The varied effects of TRAIL
signaling could be also attributed to the following fac-
tors: TRAIL resistance due to presence of decoy recep-
tors [11], number, type and functionality of TRAIL
Figure 5 (A) Kaplan Meier survival analysis in CRC patients with over expression of Trail R1 had a better overall survival of 68.1% at 5
years as compared to 53.9% with reduced TRAIL-R1 expression (p = 0.0124). (B) CRC patients Trail R2 also showed a better overall survival
as of 67.3% compared to 57.6% with reduced TRAIL-R2 expression ( p = 0.0211).
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receptors [7,12] and intracellular anti apoptotic
molecules like c-FLIP [35], IAP [36], Mcl-1 [37] and
bcl2 [38].
Although TRAIL-R1 lost its statistical significance
when included as a prognostic marker in multivariate
analysis with p27 and KRAS4A (see Additional File 1
Table S2), this does not argue against the biological role
of TRAIL-R1 in CRC as much as it reflects that p27 and
KRAS4A are a more powerful predictor of clinical out-
come of CRC than TRAIL-R1 expression. We can
hypothesize that the TRAIL-R1 functions most effec-
tively in the cells which show co-expression of p27kip1
in concordance with an earlier study [39]. Despite some
studies that show a role of Ras signaling pathway in
modulating the TRAIL system, studies on the KRAS iso-
forms - KRAS4A and KRAS 4B are lacking. Alternate
approaches to modulate the expression of KRAS iso-
forms, a greater understanding of the role(s) that each
oncoprotein plays in malignant transformation, includ-
ing the signal transduction pathways affected, is crucial
in the development of therapeutic approaches in cancer
treatment, which include the use of drugs that target
isoform-specific post-translational modifications [40]
and of antisense oligonucleotides to modulate alternative
splicing [41].
Oncogenic mutations such as ras may enhance expres-
sion of TRAIL receptors; potentially sensitizing these
tumors to TRAIL based therapies [19-21]. TRAIL-based
therapeutic strategies using TRAIL agonists could be
used in cases of human colon cancers bearing RAS
mutations. In a small cohort of 51 CRC, Oikonomou E
et al.[42] have reported a much lower incidence of
KRASG12/13 mutations(10%) and have concluded that
there is clear correlation between these mutations(KRAS
and BRAF) and upregulation of TRAIL-R1 and TRAIL-
R2. Despite lack of statistical significance they have con-
cluded that CRC with mutations in KRAS or BRAF gene
had significantly upregulated both TRAIL death recep-
tors. In our earlier study [43] KRAS gene mutations
were seen in 80/285 CRC (28.1%) and were an indepen-
dent prognostic marker for poor survival. Interestingly
we have observed a significantly higher expression of
TRAIL-R2 (p = 0.0481) in CRC subgroup lacking KRAS
mutations(75.5%) as compared to the CRC subgroup
with KRAS mutations(61.1%). In view of the recent find-
ings of KRAS mutations and PIK3CA mutations contri-
buting to resistance to EGFR inhibitors like Cetuximab,
[44,45] a better understanding of the TRAIL system
with context to KRAS mutations might be useful. The
KRAS gene has two alternative fourth exon variants that
result from differential splicing and activating mutations
affect both isoforms [46-48]. Studies in animals indicate
that KRAS4A promotes apoptosis while KRAS4B inhi-
bits it, and KRAS4B promotes differentiation [49,50]. In
our study [43], KRAS 4A a pro apoptotic isoform, in
particular was found to be an independent prognostic
marker for better survival in all CRC patients. Even in
the CRC subgroup lacking KRAS mutations KRAS4A
was associated with better survival. Furthermore, we
have observed a highly significant association of
KRAS4A and both the TRAIL receptors: TRAIL-R1(p <
0.0001) and TRAIL-R2(p < 0.0001). Considering the
tight linkage between TRAIL-R1 and KRAS4A future
studies should be conducted to understand the associa-
tion between these markers.
In summary, our study shows high TRAIL-R1 expres-
sion to be an independent prognostic marker for better
survival in colorectal cancer. High TRAIL-R1 or TRAIL-
R2 expression was associated with a less aggressive
phenotype characterized by early AJCC stage, well-
differentiated tumors, microsatellite stable cancers,
absence of KRAS mutations and expression of pro apop-
totic molecules: KRAS4A, p27kip1 and cleaved caspase 3.
Further work is needed to elucidate the biological signif-
icance of high TRAIL-R1 expression and better
outcome, and to establish the association between
TRAIL-R1 expression and response to therapy that tar-
gets this receptor. The biological effects of TRAIL in
CRC models, its enhancement of chemosensitivity with
standard chemotherapeutic agents and the effect of
endogenous TRAIL receptor levels on survival make
TRAIL an extremely attractive therapeutic target.
Table 3 TRAIL-R1 expression: Cox regression analysis for overall survival of patients with colorectal carcinoma
UNIVARIATE MULTIVARIATE
Clinical Parameters Risk Ratio (95% CI) p value Risk Ratio (95% CI) p value
Age: Above = 50 1.17 (0.80-1.74) 0.4306 1.40 (0.86 - 2.33) 0.1755
Sex: Male 1.10 (0.76-1.59) 0.6084 1.18 (0.75 - 1.87) 0.4589
Stage: III-IV 7.26 (4.34-13.03) < 0.0001 6.56 (3.67 - 12.78) < 0.0001
Grade: Poorly differentiated 1.41 (0.90-2.14) 0.1307 3.61 (1.72 - 6.80) 0.0014
MSI status: MSI-L/S 2.04 (1.14 - 4.05) 0.0149 1.90 (0.95 - 4.37) 0.0713
Histology: Adenocarcinoma 1.14 (0.67 - 2.10) 0.6499 2.28 (0.93 - 5.43) 0.0695
TRAIL-R1: Low expression 1.18 (1.11 - 2.83) 0.0196 1.84 (1.10 - 3.02) 0.0273
CI = confidence interval
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Materials and methods
Patient selection and tissue microarray construction
Four hundred forty eight patients with CRC diagnosed
between 1990 and 2006 were selected from King Faisal
Specialist Hospital and Research Centre. All CRC, 24
adenomas and 229 adjacent normal colorectal mucosa
were analyzed in a tissue microarray format. Clinical
and histopathological data were available for all these
patients. Colorectal Unit, Department of Surgery, pro-
vided long-term follow-up data. From our cohort of 448
patients treatment details were available for 310
patients:220 patients received adjuvant therapy; 90 were
treated by surgery alone and 138 patients were excluded
as we could not retrieve treatment details. Patients with
colon cancer underwent surgical colonic resection and
those with rectal cancer underwent anterior resection or
abdominoperineal resection. All node-positive colon
cancers received 5-fluorouracil-based adjuvant che-
motherapy. A vast majority of the rectal cancers
received radiotherapy alone or chemoradiotherapy prior
to surgery, followed by adjuvant chemotherapy after sur-
gery. Fixation of tissues was done overnight with 10%
neutral buffered formalin at the Pathology Laboratory of
King Faisal Specialist Hospital and Research Centre,
Riyadh. Tissue microarrays were constructed from for-
malin-fixed, paraffin-embedded colorectal carcinoma
specimens as described previously [51]. One pathologist
(PB) reviewed all tumors for grade and histological sub-
type. Institutional Review Board (IRB) of the King Faisal
Specialist Hospital & Research Centre approved the
study.
Immunohistochemistry (IHC)
Tissue microarray slides were processed and stained
manually. The streptavidin-biotin peroxidase technique
with diaminobenzidine as chromogen was applied. For
antigen retrieval, Dako Target Retrieval Solution was
used at a pH of 6 for TRAIL-R1 and pH of 9 for
TRAIL-R2 was used, and the slides were microwaved at
750W for 5 minutes and then at 250W for 30 minutes.
Primary antibodies used, their dilutions, and incidences
are listed in Additional File 1 Table S5. The specificity
of these antibodies for TRAIL and its receptors has
been previously assessed by immunohistochemistry
[28,52], or by Western blot [53]. Endogenous peroxidase
activity was quenched using 3% hydrogen peroxidase.
Endogenous biotin was blocked and all slides were
counterstained with hematoxylin, dehydrated, cleared,
and cover slipped with premount. Only fresh cut slides
were stained simultaneously to minimize the influence
of slide ageing and maximize repeatability and reprodu-
cibility of the experiment. As controls, we used a tissue
microarray control block comprising multiple cores
from normal tissue from various sites, common epithe-
lial cancers and colon cancer cell lines. Omission of the
primary antibody also served as a negative control for
TRAIL, TRAIL-R1 and -R2 staining.
Immunohistochemistry Assessment
TRAIL-R1, TRAIL-R2 and TRAIL expression was cate-
gorized by doing an H score [54,55]. Each tissue micro-
array spot was assigned an intensity score from 0-3(I0,
I1-3) and proportion of the tumor staining for that inten-
sity was recorded as 5% increments from a range of 0-
100(P0, P1-3). A final H score (range 0-300) was obtained
by adding the sum of scores obtained for each intensity
and proportion of area stained (H score = I1XP1+I2XP2
+I3XP3). CRCs were grouped into two groups based on
X-tile plots for TRAIL-R1: one with complete absence
or reduced staining (H score = 0-110) and the other
group showed over expression (H score > 110) depend-
ing on the H score. Similarly, X-tile plots were used to
stratify the CRC cases into two groups for TRAIL-R2
and TRAIL. X-tile plots were constructed for assessment
of biomarker and optimization of cut off points based
on outcome as has been described earlier [56,57]. For
cleaved caspase-3 expression, we used the antibody
clone C5A-1 from Cell signalling technologies as
described previously [43]. CRCs were grouped into two
groups based on X-tile plots: one with complete absence
or reduced staining (H score = 0-9 for low cleaved cas-
pase3); and the other group showed over expression (H
score >9 for high cleaved caspase 3). Grading of p27
nuclear protein staining was based on proportion or
percentage of cell nuclei staining and was semi quanti-
fied as high or low. Nuclear protein expression of
epithelial cells only was scored as high if 50% or more
of the nuclei were stained or low if < 50% were stained
as described previously [58]. This scoring criteria has
been used earlier [59].
Mutational analysis of the KRAS gene
KRAS mutations were done as described earlier [43].
Briefly the step-down cycling condition was used for
the detection of exon 1 mutation of the KRAS gene.
After 10 minutes denaturing at 95°C, the PCR was run
with each temperature for 1 min at five step-down
steps, for two cycles each. The denaturing temperature
was 95°C and the extension temperature was 72°C for
each step, with an annealing temperature of 66°C, 64°
C, 62°C, 60°C, and 58°C from the first to the last step.
The PCR was finally run at 95°C, 58°C, and 72°C, each
for 1 min for 35 cycles, followed by an elongation at
72°C for 5 min. The PCR products were subseque-
ntly subjected to direct sequencing PCR with BigDye
terminator V 3.0 cycle sequencing reagents (Applied
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Biosystems, Foster City, CA, USA). The samples were
finally analysed on an ABI PRISM 3100xl Genetic Ana-
lyzer (Applied Biosystems).
Microsatellite instability
Allelic imbalances were measured by performing micro-
satellite analysis on all matched normal and tumor tis-
sue by PCR amplification as described previously [60]. A
reference panel of five pairs of microsatellite primers,
comprising two mononucleotide microsatellites (BAT25,
BAT26) and three dinucleotide microsatellites (DS123,
D5S346 and D17S250) were used to determine tumor
MSI status. Multiplex PCR was performed in a total
volume of 25 ml using 50 ng of genomic DNA, 2.5 ml
10 Taq buffer, 1.5 ml MgCl2 (25 mM), 10 pmol of
fluorescent-labeled primers, 0.05 ml dNTP (10 mM) and
0.2 ml Taq polymerase (1 U ml 1 ) (all reagents were
from Qiagen Inc., Valencia, CA, USA). PCR was per-
formed using an MJ Research PTC-200 thermocycler.
The PCR conditions were as follows: after an initial 10
min denaturation step at 95 1C, 40 amplification cycles
were performed consisting of 40 s at 95 1C, 40 s at 54
1C and a 1 min elongation step at 72 1C. Amplification
was completed with a final extension step at 72 1C for 7
min. The fluorescent-labeled products were finally ana-
lysed on an ABI PRISM 3100 l Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA). Tumors
were classified as MSI if at least two or more markers
out of the five were unstable and as MSS if only one or
none of the markers was unstable.
Statistical Analysis
The JMP8 (SAS Institute, Inc., Cary, NC) software pack-
age was used for data analyses. Survival curves were
generated using the Kaplan-Meier method, with signifi-
cance evaluated using the Mantel-Cox log-rank test.
Risk ratio (relative risk for death) was calculated using
the Cox Proportional Hazard model in both univariate
and multivariate analyses. Comparisons between groups
were made with the paired Student’s t-test. Chi-square
tests were used to examine relationship between nom-
inal variables. The limit of significance for all analyses
was defined as a p-value of 0.05.
Additional material
Additional file 1: Additional file 1. Table S1. Clinico-pathological
characteristics and TRAIL expression in patients with colorectal
carcinoma. Table S2. Cox regression analysis for overall survival of
colorectal carcinoma patients: TRAIL-R1, KRAS4A and p27kip1. Table S3.
Trail-R1 & R2 co-expression: Cox regression analysis for overall survival of
patients with colorectal carcinoma. Table S4. Trail R1 in Adjuvant treated
Group: Cox regression analysis for overall survival of patients with
colorectal carcinoma. Table S5. Antibodies used for tissue micro array
Immunohistochemical analysis.
Additional file 2: Additional file 2. Prognostic significance of TRAIL-R1
& TRAIL-R2 in early and late stage CRC and Kaplan Meier survival analysis.
[A] In the early Stage subgroup (I and II) CRC patients TRAIL-R1
expression was not associated with prognostic outcome (p = 0.4703). [B]
In the advanced Stage subgroup(III and IV) CRC patients with over
expression of TRAIL-R1(n = 157) had a better overall survival of 48.8% at
5 years as compared to 26.0% with reduced TRAIL-R1 expression (n = 30;
p = 0.0060). [C] In the early Stage subgroup (I and II) CRC patients TRAIL-
R2 expression was not associated with prognostic outcome (p = 0.5613).
[D] In the advanced Stage subgroup(III and IV) CRC patients with over
expression of TRAIL-R2 (n = 112) had a better overall survival of 50.0% at
5 years as compared to 35.2% with reduced TRAIL-R2 expression (n = 70;
p = 0.0263).
Additional file 3: Additional file 3. Prognostic significance of TRAIL-R1
& R2 in CRC with Stage II and III and Kaplan Meier survival analysis. [A] In
the Stage subgroup(II and III) CRC patients with over expression of TRAIL-
R1(n = 226) had a better overall survival of 67.6% at 5 years as compared
to 63.1% with reduced TRAIL-R1 expression (n = 41; p = 0.2508). [B] In
the Stage subgroup(II and III) CRC patients with over expression of TRAIL-
R2(n = 149) had a better overall survival of 71.3% at 5 years as compared
to 57.3% with reduced TRAIL-R2 expression (n = 105; p = 0.0088).
Additional file 4: Additional file 4. Prognostic significance of co-
expression of TRAIL receptors: TRAIL-R1 and TRAIL-R2 in CRC and Kaplan
Meier survival analysis. The CRC subgroup with overexpression of TRAIL-
R1 and TRAIL-R2 (n = 191) had a better overall survival of 69.5% at 5
years as compared to Reduced TRAIL-R1 and TRAIL-R2 expression of
57.9% (n = 145; p = 0.0107).
Additional file 5: Additional file 5. Prognostic significance of TRAIL-R1
& TRAIL-R2 in CRC based on adjuvant therapy and Kaplan Meier survival
analysis. [A] CRC patients with over expression of TRAIL-R1 in adjuvant
treated group had a better overall survival of 70.6% at 5 years as
compared to 48.4% with reduced TRAIL-R1 expression (n = 203; p =
0.0033). [B] In the non-adjuvant treated group TRAIL-R1 expression was
not associated with prognostic outcome (p = 0.8801). [C] CRC patients
with over expression of TRAIL-R2 in adjuvant treated had a better overall
survival of 73.5% at 5 years as compared to 46.5% with reduced TRAIL-R2
expression (n = 168; p = 0.0998). [D] In the non-adjuvant treated group
TRAIL-R2 expression was not associated with prognostic outcome (p =
0.8069).
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